Healio

Phase 2b study of iobenguane I 131 shows promise for rare neuroendocrine tumors

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The registrational phase 2b trial designed to evaluate ...
Medindia

Side effect(s) of Iobenguane I 123 Injection

Review the side-effects of Iobenguane I 123 Injection as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
Medindia

Iobenguane I 123 Injection

Learn the correct pronunciation of the Iobenguane I 123 Injection, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special ...
Medscape

New FDA Orphan Drugs: Nitroimidazole PA-824, 3'-deoxyadenosine, Iobenguane I 131

August 24, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for nitroimidazole PA-824 for the treatment of tuberculosis, 3'-deoxyadenosine for the treatment of ...
ascopubs.org

Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi ...

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). This is an ASCO ...
Business Insider

Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and ...
FierceBiotech

FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Child

PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare, a unit of General Electric Company (NYSE:GE), today announced that the Food and Drug Administration (FDA) has approved AdreView TM (Iobenguane I 123 ...
FiercePharma

FDA Approves GE Healthcare's AdreView™ (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients

GE Healthcare today announced the U.S. Food and Drug Administration (FDA) approval of a new indication for AdreView™ (Iobenguane I 123 Injection), the first and only FDA approved molecular imaging ...
Business Insider

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and ...
ascopubs.org

Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with unresectable, locally advanced or metastatic ...

Molecular characterization of the tumour microenvironment in neuroendocrine malignancy. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a full text ...
AOL

CORRECTING and REPLACING FDA Approves GE Healthcare's AdreView™ (Iobenguane I 123 Injection) for Car

CORRECTING and REPLACINGFDA Approves GE Healthcare's AdreView™ (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients AdreView is the First and Only Imaging Agent Approved ...